跳到正文
原文
Medical Xpress·· 2026-10-14AI 评分40

新研究揭示介入放射学在肝癌治疗中日益增长的角色

New paper outlines growing role of interventional radiology in liver cancer treatment

AI 导读

发表于《Journal of Vascular and Interventional Radiology》的研究显示,介入放射科医师为约51%的Medicare肝癌患者提供治疗,涵盖TACE等疗法。该研究分析了2016–2021年数据,指出介入放射学以较低成本实现了与肿瘤科相当或更优的疗效。

正文
surgery
Credit: Unsplash/CC0 Public Domain

Interventional radiologists (IRs) provide patients with primary and secondary liver cancer with high-quality, high-impact care in a more cost-efficient way than other specialties, according to a study published online in the Journal of Vascular and Interventional Radiology.

The study reviewed Medicare data from 2016–2021 covering approximately 110,000 patients per year. The authors found that IRs treated nearly 51% of Medicare patients with liver cancer, with the volume increasing over time as routine oncologic care increasingly relies on IR for essential support services (such as image-guided biopsy, venous access and drainage) and for therapeutic solutions, such as percutaneous ablation and transarterial therapies.

"Liver cancer demands complex, multidisciplinary care, and IRs have a central and transformative role to play on this care team," said SIR Secretary Nishita Kothary, M.D., FSIR, an interventional radiologist and professor at the Stanford University School of Medicine. Kothary was co-author of the paper.

IRs are increasingly specializing in oncology and delivering therapeutic treatments for the cancer itself, such as transarterial chemoembolization (TACE), transarterial radioembolization (TARE) and percutaneous thermal and nonthermal ablation.

"IOs harness minimally invasive, image-guided techniques to deliver targeted therapies that can be curative, adjunct to systemic therapies, or even serve as a bridge to organ transplantation," said Kothary. "These therapies can have fewer side effects than systemic therapies and a faster recovery time, making the treatment less onerous on the patient's quality of life."

Primary liver cancer is the third leading cause of cancer-related death worldwide, with approximately 900,000 new cases reported annually, 43,000 of which are in the United States. Metastatic liver cancer is an equally formidable problem, as it is a common metastasis from many common cancers, including colorectal and breast cancers. With so many lives affected, these high-efficacy, low-side-effect and lower-cost treatments can have an impact.

Physician payments and patient out-of-pocket costs rose during the study period, with oncology accounting for the steepest increases (72% over the five-year period). However, the overall cost burden of IR to the health care system was comparably lower.

IR accounted for 7.4% of total payments while performing 11.7% of the work relative value units (wRVUs), a standard, Medicare-derived metric used to measure the time, skill and intensity a physician invests in a patient service. By comparison, oncologists accounted for 52.5% of total payments while performing 13.7% of wRVUs, and radiation oncologists accounted for 5.4% of payments while performing 4.5% of wRVUs.

"IR delivers the same quality of care at a fraction of the cost of oncologists, which is potentially more valuable to patients, payers and health care systems, especially when you consider the fact that recovery times are faster and hospital stays are often not required following an IR treatment," said SIR Treasurer C. Matthew Hawkins, M.D., MBA, FSIR, an interventional radiologist and professor at the Emory University School of Medicine. He is co-author of the paper.

"As payers and regulators push for more cost-effective care, the urgency for IRs to be present at the table in discussions of cancer care policy, cost and resource allocation only grows."

"IR can offer cost-efficient care for hepatobiliary disease with comparable or improved clinical efficacy as compared to alternative treatment options offered by other specialties," Hawkins said. "IRs must be a part of the discussion, especially as we move to a system of alternative payment models to control costs of care."

Publication details

Nishita Kothary et al., Quantifying the Role of Interventional Radiology in Managing Patients with Hepatobiliary Cancers, Journal of Vascular and Interventional Radiology (2026). DOI: 10.1016/j.jvir.2026.109090

Journal information: Journal of Vascular and Interventional Radiology

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: New paper outlines growing role of interventional radiology in liver cancer treatment (2026, October 13) retrieved 13 October 2026 from https://medicalxpress.com/news/2026-10-paper-outlines-role-interventional-radiology.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com